Tag: RE-LY trial
Daniel Whittaker
How Dabigatran Is Changing Stroke Prevention for Atrial Fibrillation
Explore how dabigatran, a direct thrombin inhibitor, reshapes stroke prevention in atrial fibrillation with evidence, dosing tips, and patient‑focused guidance.
Read MoreRecent News
